Clinical trials: Metabolism and Excretion
Healthy
AME Study of [14C]-YH4808 in Healthy Male Subjects
The purpose of this study is to determine the absorption, metabolism, and excretion (AME) kinetics of YH4808 and to determine and characterize metabolites present in plasma, urine, and feces in man following a single dose of…
- Trial name
- NCT01825707
- Testing
- [14C]-YH4808 200 mg
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy Male Participants
A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants
The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.
- Trial name
- NCT06088264
- Testing
- BMS-986322
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Healthy Male Subjects
A Human AME Study for Omaveloxolone
This study will assess the pharmacokinetics (PK), mass balance, metabolite profiles, and rates and routes of elimination of [14C] omaveloxolone and derived metabolites following administration as a single 150 mg (containing…
- Trial name
- NCT03931590
- Testing
- [14C]-Omaveloxolone
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Kidney Disease Patients
Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients
This is a single-center, nonrandomized, and open design study to investigate metabolism and excretion of HSK21542 in maintenance hemodialysis patients.
- Trial name
- NCT06238388
- Testing
- HSK21542 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Cancer
A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer
This study investigates the pharmacokinetics of YM155, identifies the metabolic profile of YM155 and evaluates the safety and tolerability of YM155 after a 3-hour infusion in patients with advanced cancer
- Trial name
- NCT01023386
- Testing
- YM155
- Where
- Hungary
- Volunteers
- 6 people
- Sponsor
- Astellas Pharma Inc
Ulcerative Colitis
A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.
The purpose of this randomized, open-label, parallel-group study is to determine how the body absorbs and eliminates mesalamine following administration of either 30 mg/kg/day, 60 mg/kg/day or 90 mg/kg/day as 400 mg…
- Trial name
- NCT00254618
- Testing
- mesalamine
- Where
- 22 sites in United States
- Volunteers
- 34 people
- Sponsor
- Warner Chilcott
Healthy Volunteers
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential
This is an open-label, single-center, two part study in healthy female subjects of non-childbearing potential to investigate the absorption, metabolism, and excretion of [14C]-GDC-9545 (Part 1), the absolute bioavailability of…
- Trial name
- NCT04680273
- Testing
- [14C]-GDC-9545, GDC-9545 Solution for Infusion, GDC-9545/F12 Capsule
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Cholestasis
Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat
Absorption, metabolism and excretion of linerixibat have been studied in previous clinical trials. However, no dedicated clinical studies of drug absorption, metabolism, and excretion have been conducted for linerixibat.
- Trial name
- NCT03992014
- Testing
- Linerixibat tablet, [14C]-linerixibat intravenous infusion, Linerixibat oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)
The purpose of this study is to learn what happens to elpipodect in a healthy person's body over time.
- Trial name
- NCT06626464
- Testing
- [14C]Elpipodect
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteer
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of [14C]-NX-5948.
- Trial name
- NCT06691828
- Testing
- NX-5948
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.
Advanced Solid Tumors, Pharmacokinetics of 14C-OSI-906
A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body
The purpose of this study is to evaluate the pharmacokinetics, in particular the routes of excretion and extent of metabolism of OSI-906 after a single oral dose of 14C-labeled OSI-906.
- Trial name
- NCT01529684
- Testing
- radio-labeled OSI-906, OSI-906
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Cancer, Healthy Volunteers
Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women
Primary Objectives: To assess the excretion balance after oral and IV administration of [14C]-SAR439859 To assess PK of total radioactivity, [14C] -SAR439859 and its metabolite (M7) after IV administration of [14C]-SAR439859 and…
- Trial name
- NCT04940026
- Testing
- amcenestrant, [14C]-SAR439859 microtracer, [14C]-SAR439859
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteer
Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125
This study is conducted to evaluate the absolute bioavailability, metabolism and elimination pathways of AQX-1125 in healthy male and female subjects.
- Trial name
- ADME (NCT03185195)
- Testing
- AQX-1125 Oral Tablet, [14C]-AQX-1125 IV, [14C]-AQX-1125 Oral Solution
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Healthy
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19.
- Trial name
- NCT05580003
- Testing
- PF-07817883, Midazolam, Moxifloxacin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435
The purpose of this study is to determine the absorption, metabolism, excretion; and to evaluate the safety and tolerability of BMS-986435 in healthy male participants Participants will be admitted to the study site for 3 weeks.
- Trial name
- NCT05686096
- Testing
- MYK-224
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
The purpose of this study is to gain an understanding of how the experimental anti-cancer drug, rigosertib, is metabolized in the body and excreted in the urine and feces after it is given as an intravenous infusion.
- Trial name
- NCT02030639
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Traws Pharma, Inc.
Chronic Hepatitis B
A Study to Evaluate the Mass Balance Absorption and AME of VBR
This Phase 1 Study will determine the mass balance recovery, absorption, metabolism, and excretion of [14C] Vebicorvir in healthy male subjects
- Trial name
- NCT04637139
- Testing
- Vebicorvir (VBR)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Healthy
What the Body Does to Foliglurax in Healthy Volunteers
This study evaluates how the body takes up and gets rid of foliglurax after swallowing a liquid dose.
- Trial name
- Foliglurax (NCT04002895)
- Testing
- Foliglurax
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S